| HOME >> BIOLOGY >> TECHNOLOGY |
LANSING, Mich., June 20, 2011 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that it has acquired the assets of the VeroMara seafood testing laboratory from its parent company, GlycoMar Ltd.
Based in Oban, Scotland, VeroMara offers testing services to the shellfish and salmon aquaculture industries. VeroMara's services include testing for shellfish toxins, general foodborne pathogens, including E. coli, noroviruses, and salmon husbandry. VeroMara recorded revenues of approximately $800,000 (U.S.) in its most recently completed fiscal year. Terms of the acquisition were not disclosed.
"The acquisition of VeroMara deepens Neogen's advancement into the aquatic sciences," said James Herbert, Neogen's CEO and chairman. "VeroMara's services are complementary and a nice fit with our existing product lines for the seafood industry, including one of our biggest food safety diagnostic products — our histamine tests for the tuna industry. The VeroMara purchase also provides Neogen with key collaborative relationships with influential aquaculture partners, and increased access to important international markets.
"Our new operation in Oban will work in close cooperation with our Neogen Europe headquarters in Ayr, Scotland, providing expanded products and services to a larger customer base," Herbert continued. "Our sales and marketing operations in Ayr have the capability to expand VeroMara's business to several other European countries."
"The sale of our VeroMara testing service allows GlycoMar to focus on our core business — marine natural product research and development," said Dr. Charles Bavington, GlycoMar's managing director. "We are pleased to have VeroMara join Neogen, a company we respect as being one of the world leaders in food safety. This transition will guarantee uninterrupted quality service to our customers."
'/>"/>
| SOURCE Neogen Corporation Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. William T. Boehm Joins Neogens Board of Directors
2. Neogen Reports 27% Increase in Quarterly Net Income
3. Neogens Rapid Test for Salmonella enteritidis Receives FDA Approval
4. Neogen Names Quinlan as CFO
5. Neogen Reports 33% Increase in Net Income
6. Neogen Corporation Announces 2nd Quarter Results Conference Call
7. Neogens Rapid Test for Salmonella enteritidis Receives AOAC Approval
8. NeoGenomics Schedules its Q2 2010 Earnings Release for July 29, 2010
9. NeoGenomics to Present at Noble Financials 6th Annual Equity Conference on Monday, June 7th
10. Neogen Corporation Announces 3rd Quarter Results Conference Call
11. Neogen Reports 18% Increase in Net Income
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |